In 1987 we reported the results of the Scottish tamoxifen trial, conducted between 1978 and 1984 . (Breast Cancer Trials Committee, 1987 . In that trial, following mastectomy for primary breast cancer, 1323 women were randomly allocated either to receive adjuvant tamoxifen, 20 mg daily for 5 years, or to a control group in which tamoxifen was to be given only on relapse of disease. The results unequivocally supported benefit from tamoxifen as adjuvant systemic therapy. In 1984, we proposed that consenting disease-free women in the study arm should be offered further randomisation, at 5 years, to continue or to stop tamoxifen.
Methods
Eligibility for this second, subsidiary trial was disease-free status after 5 years of continuous tamoxifen therapy in the parent trial. Women entering the parent trial before March 1980 were ineligible, as most had already stopped tamoxifen. At 41/2 years from entry, each subsequent patient believed to be eligible had her secondary option selected in the Trials Office by randomisation within each of five subgroups (marked with an asterisk in Table I ). The option was sent in a sealed envelope to the clinician responsible for follow-up in readiness for the 5th annual review. Only 2 of 90 clinicians refused to participate. Provided eligibility criteria were fulfilled and the patient consented to randomisation, the envelope was opened, the appropriate instruction given and Between February 1985 and August 1989, 169 patients were allocated to stop tamoxifen and 173 to continue. In the event, 14 of the former decided to continue the drug and two of the latter to stop. These 16 patients have been included in the analysis as randomised in accordance with an intentionto-treat policy. Follow-up and recording of information was as in the parent trial, patients being seen annually or on relapse. As many patients have since ceased routine hospital review, progress reports have been obtained from their general practitioners, resulting in information updated to 1993 for all but two patients. Median follow-up for living patients from the date of rerandomisation was 6.2 (1.0-9.1) years.
Results
The distribution of age at secondary randomisation and the original characteristics of the patients and their tumours were comparable ( Table I ). The median duration of tamoxifen therapy for the 169 randomised to stop (including 14 who refused to do so) is 60 (56-162) months and for the 173 randomised to continue (including two who elected to stop) is 128 (58-169) months. To date, 120 and 113 patients remain alive and well in the 'stop' and 'continued' groups respectively. A total of 105 (61%) of those randomised to continue and 10 of the 14 who refused to stop remain on tamoxifen; a further 11 in the 'continued' group elected to stop after a median duration of 9 (6.5-11.5) years total use.
The distribution of events after rerandomisation at 5 years is given in Table II , showing that the number with confirmed relapse was greater, but not significantly so, in those continuing tamoxifen (38) than in those stopping (28); 17 (61%) of the latter group restarted tamoxifen on relapse, at a median interval after stopping of 47 (14-84) months. In six patients in each group, relapse was deemed uncertain, being of doubtful origin or of unknown site, although death was certified as being due to breast cancer.
Event-free survival curves (for relapse or death without relapse) are shown in Figure 1 . The hazard ratio for these events is 1.27, with a 95% confidence interval of 0.87-1.85, indicating a non-significant benefit for those randomised to stop. The total number of deaths without relapse was similar in the two groups; of them, nine patients died from cardiac disease within 2 -96 (median 72) months of stopping tamoxifen compared with six who continued beyond 5 years and died 1-13 months after rerandomisation. Indirect evidence from the combined analysis of tamoxifen trials indicated that benefit from treatment for 2-5 years was greater than that from less than 2 years (Early Breast Cancer A possible criticism of this study is the sample size, which is not adequate to detect small differences between the treatment groups. The trial size was limited by the availability in the 1980s of patients with 5 years successful adjuvant treatment with tamoxifen, and this study is based on all patients available to us. It represents the most mature trial of late randomisation to continuous tamoxifen. Despite its limited size, the confidence limits we report allow us to conclude that, if continuing tamoxifen beyond 5 years is beneficial, the extent of that benefit is relatively modest, and not comparable with the benefits seen in the first 5 years of treatment. More precise estimates of the benefit and risk from long-term tamoxifen would be welcome, and we would urge participation in ongoing trials addressing this question. However, until such evidence is accumulated. there is little to suggest that tamoxifen should be prescribed routinely beyond 5 years.
